INTRODUCTION
Single-strand DNA binding proteins (SSBs) regulate DNA replication, recombination, and repair. In eukaryotes, the major SSBs at replication forks include replication protein A (RPA) and RAD51. RAD51 is best known for its ability to form nucleoprotein filaments on resected double-strand breaks and catalyze strand invasion for homologous recombination (HR) (Kowalczykowski, 2015) . RAD51 also has at least two functions at stalled replication forks. First, it cooperates with SNF2 family DNA translocases to promote fork reversal (Bé tous et al., 2012; Ciccia et al., 2012; Kile et al., 2015; Vujanovic et al., 2017; Zellweger et al., 2015) . Second, in cooperation with BRCA2, RAD51 inhibits degradation of the nascent DNA after fork reversal of persistently stalled forks (Hashimoto et al., 2010; Lemaç on et al., 2017; Mijic et al., 2017; Schlacher et al., 2011; Taglialatela et al., 2017) . In addition to BRCA2 deficiency, loss of several other HR proteins causes nascent-strand degradation (Higgs et al., 2015; Schlacher et al., 2011 Schlacher et al., , 2012 . At least two nucleases, MRE11 and DNA2, are involved. How these pathways work together to maintain fork stability is still unclear. Small amounts of nuclease action could be beneficial to remove DNA lesions or end binding proteins, control the amount of single-strand DNA (ssDNA) at a stalled fork, remodel the reversed fork, and promote fork restart (Thangavel et al., 2015) ; however, unregulated degradation causes genome instability (Schlacher et al., 2011 (Schlacher et al., , 2012 .
Fork reversal is independent of BRCA2, thus explaining how nascent strand degradation can proceed from reversed forks in BRCA2-deficient cells (Mijic et al., 2017) . How RAD51 gains access to persistently stalled forks without BRCA2 to mediate an exchange with RPA is unknown. Nonetheless, the need for RAD51 to promote reversal explains why silencing RAD51 using RNAi is reported to not cause degradation (Mijic et al., 2017; Thangavel et al., 2015; Zellweger et al., 2015) . Paradoxically, some RAD51 mutations and inhibitors do yield fork degradation (Dungrawala et al., 2017; Kolinjivadi et al., 2017; Leuzzi et al., 2016; Mijic et al., 2017; Su et al., 2014; Taglialatela et al., 2017; Zadorozhny et al., 2017) , raising the possibility that either fork reversal is not always required for nucleases to degrade the nascent strands or these ways of inhibiting RAD51 only interfere with some of its activities. Finally, fork degradation may be an important determinant of the viability of BRCA2-deficient cells and their sensitivity to PARP inhibitors Ding et al., 2016; Dungrawala et al., 2017; Rondinelli et al., 2017) .
We recently identified a SSB with similarity to RPA named RADX (Dungrawala et al., 2017) . RADX negatively regulates RAD51 accumulation at replication forks, and we proposed that this regulation prevents inappropriate RAD51-dependent fork reversal in the absence of added replication stress. Presumably, at persistently stalled forks, the negative regulation of RAD51 by RADX is overcome by the positive regulation conferred by BRCA2 to sustain fork protection. Consistent with this hypothesis, knocking out RADX restores fork protection to BRCA2-deficient cells.
In this study, we sought to further test the hypothesis that RADX acts as a RAD51 antagonist and use RADX as a tool to investigate how fork protection pathways operate. Our findings support the model that RADX is a RAD51 antagonist that ensures the right amount of RAD51 fork reversal and protection activities to maintain genome stability. We also find a requirement for higher cellular levels of RAD51 to protect persistently stalled forks than to promote fork reversal.
RESULTS
RADX Silencing Suppresses MRE11-Dependent Fork Degradation in Cells with Impaired RAD51 Filament Stability Multiple HR proteins, including BRCA1, protect the nascent DNA at replication forks from MRE11 digestion by promoting RAD51 filament stability. To test the hypothesis that silencing RADX would restore fork protection in cells with decreased RAD51 activity, we utilized small interfering RNA (siRNA) to deplete BRCA1 in U2OS cells and induce nascent strand degradation (Schlacher et al., 2012) . Silencing RADX is sufficient to restore fork protection to BRCA1-depleted cells ( Figures 1A, 1B , and S1). This is not an off-target effect of siRNA because deletion of RADX using CRISPR-CAS9 also prevents nascent strand degradation after BRCA1 silencing ( Figure 1C ). RADX deficiency also restores fork protection to BRCA1-depleted RPE-hTERT cells ( Figure 1D ), indicating that this effect is not cell type specific. We did not observe any defects in fork protection upon RADX depletion alone, either by siRNA or RADX deletion (Figure 1 ). These results differ from a previous report that suggested RADX deficiency causes nascent strand degradation (Schubert et al., 2017) . The reason for this difference is unclear.
In addition to their function in interstrand crosslink repair, the Fanconi anemia (FA) pathway proteins FANCA and FANCD2 also prevent MRE11-dependent nascent strand degradation (Schlacher et al., 2012) . The exact mechanism by which these proteins act is unknown, but because RAD51 overexpression rescues the fork degradation in FA cells, we predicted that RADX depletion should also suppress this phenotype. Indeed, silencing FANCA or FANCD2 in U2OS cells causes fork degradation and silencing RADX restores fork protection to these cells ( Figures 1E, 1F , and S1). As expected, silencing RADX also restores fork protection to fibroblasts harboring a FA-patientderived mutation in FANCD1/BRCA2 ( Figure 1G ). RAD51 T131P is an FA-associated, dominant-negative mutant (Wang et al., 2015) . Patient-derived fibroblasts harboring this mutation are defective in RAD51 fork protection but are proficient in HR repair (Kolinjivadi et al., 2017; Mijic et al., 2017; Wang et al., 2015; Zadorozhny et al., 2017) . We reasoned that, because the cells harboring the T131P allele exhibit only a partial loss of RAD51 function, improving RAD51 function by RADX silencing should restore fork protection in these cells. As predicted, loss of RADX prevented the nascent strand degradation observed in the T131P cells ( Figure 1H ). These data further support the model that RADX loss facilitates increased RAD51 function at persistently stalled replication forks and prevents MRE11 nuclease action.
Restoration of Fork Protection to BRCA1-Deficient U2OS Cells Does Not Cause PARP Inhibitor Resistance
Fork protection may be an important determinant of the chemosensitivity of BRCA-deficient cells to PARP inhibitors like olaparib (Ray Ding et al., 2016) . Consistent with this idea, RADX silencing not only confers fork protection to BRCA2 mutant cells but also improves their viability and resistance to olaparib, even though it does not alter HR (Dungrawala et al., 2017 ). Therefore, we tested whether the restoration of fork protection in BRCA1-deficient RADXD cells is accompanied by an increase in cell viability and olaparib resistance. BRCA1 knockdown reduces U2OS cell viability, and RADX deletion conferred a small but significant increase in viability to BRCA1-depleted cells in the absence of any drug ( Figures 1I and S1) , consistent with what was observed in BRCA2-deficient cells (Dungrawala et al., 2017) . However, unlike in BRCA2-deficient cells, RADX loss did not confer olaparib-resistance to BRCA1-depleted U2OS cells ( Figure 1H ). RADX loss also did not confer hydroxyurea or camptothecin resistance to BRCA1-depleted cells ( Figures S2A-S2C ). In fact, the hydroxyurea (HU) sensitivity caused by silencing RADX or BRCA1 by themselves is further increased in cells deficient for both proteins. Thus, despite restoring fork protection to BRCA1-deficient cells, RADX deficiency does not necessarily improve their sensitivity to replication-stress-inducing agents.
Loss of RADX Protects against DNA2-Dependent Fork Degradation
Thus far, our results indicate that silencing RADX can suppress fork degradation that is caused by RAD51 filament instability and MRE11 nuclease activity. Recently, BOD1L was shown to suppress fork degradation by promoting RAD51 filament stability, but the degradation in BOD1L-deficient cells is MRE11 independent. Instead, DNA2 degrades the nascent DNA in this setting (Higgs et al., 2015) . To test whether RADX also regulates fork protection in cases where the degradation is dependent on DNA2, we utilized siRNA against BOD1L and RADX. As reported previously, knocking down BOD1L causes DNA2-dependent nascent strand degradation ( Figure S3 ). RADX silencing restored fork protection to the BOD1L-deficient cells (Figures 2A and S1 ). Thus, RADX deficiency restores fork protection irrespective of the nuclease mediating the degradation.
DNA2 also degrades nascent DNA in U2OS cells without any genetic perturbation when these cancer cells are treated with HU for long times (Thangavel et al., 2015) . In contrast to cells with compromised RAD51, RADX deletion does not restore fork protection in this circumstance ( Figure 2B ).
Overexpression of RADX Causes Nascent Strand Degradation that Is Rescued by Inhibition of MRE11 or ZRANB3
Whereas silencing RADX can restore fork protection to RAD51-compromised cells, RADX overexpression causes nascent strand degradation (Dungrawala et al., 2017) . If the fork degradation is due to reduced RAD51 function, then it should be dependent genetically on the same factors that cause nascent strand degradation in BRCA2-deficient cells, including the MRE11 nuclease and the fork reversal enzymes SMARCAL1 and ZRANB3 (Kolinjivadi et al., 2017; Mijic et al., 2017; Taglialatela et al., 2017) . As predicted, inhibiting MRE11 ( Figure 2C) , depleting SMARCAL1 or ZRANB3, rescues the fork degradation caused by RADX overexpression ( Figures 2D, 2E , and S1). We also observed a partial rescue of the RADX overexpressioninduced fork degradation by silencing DNA2 ( Figure 2F ). The ability of either DNA2 or MRE11 inhibition to rescue fork degradation in cells overexpressing RADX is consistent with the idea that RAD51 destabilization can lead to either MRE11-dependent degradation, as in BRCA2-deficient cells, or DNA2-dependent degradation, as in BOD1L-deficient cells.
Differential Requirements of RAD51 in Fork Reversal and Protection RADX deficiency in unstressed cells causes replication fork breakage that can be rescued by silencing fork reversal proteins, including RAD51, ZRANB3, and SMARCAL1 (Dungrawala et al., 2017) . Thus, we hypothesized that RADX prevents fork reversal by antagonizing RAD51 at unstressed forks, a model that is consistent with the reduced amount of RAD51 at forks in RADX-overexpressing cells (Dungrawala et al., 2017) . However, if RAD51 is required for fork reversal, which is in turn required for fork degradation, we might have expected that RADX overexpression in HU-treated cells would inhibit RAD51-dependent fork reversal, yielding stable nascent strands instead of the fork degradation that we observed. A possible explanation is that different RAD51 functions could be needed for fork reversal and fork protection and RADX only antagonizes the fork protection function. Alternatively, the same RAD51 function could be required for both reversal and protection, but more of it may be needed for fork protection than fork reversal. Consistent with the second hypothesis, knocking down RAD51 with multiple different siRNAs yields different phenotypic outcomesfork stability or degradation ( Figure 3A) . Importantly, titrating the amount of a potent RAD51 siRNA into cells to yield partial RAD51 knockdown initially yields fork degradation at low concentrations and fork protection at higher concentrations ( Figure 3B ). The same result is observed with a second potent RAD51 siRNA ( Figure 3C ). These results indicate that the different siRNA results are not due to off-target effects but rather that the amount of RAD51 in the cell determines whether forks reverse and are then protected from nucleases. Consistent with this interpretation and our model that RADX negatively regulates RAD51, even a modest knockdown of RAD51 with an siRNA concentration that caused fork degradation in wild-type U2OS cells is sufficient to prevent degradation in U2OS cells overexpressing RADX ( Figure 3D ). This is presumably because the combination of partial RAD51 knockdown by siRNA and RAD51 inhibition by overexpressing RADX reduces RAD51 activity below the threshold required to promote fork reversal.
RADX Outcompetes RAD51 for ssDNA but Is Expressed at Lower Levels To investigate the mechanism by which RADX antagonizes RAD51, we considered whether they could compete for the same ssDNA ligand. We performed competition experiments with RADX pre-bound to the DNA followed by addition of increasing amounts of RAD51 ( Figure 4A ) or experiments with RAD51 pre-bound to the DNA followed by incubation with increasing RADX concentrations ( Figure 4B ). Low concentrations of RADX (1 nM) are sufficient to fully bind the ssDNA ligand (Figure 4A, lane 2) , whereas over 20 mM RAD51 is needed ( Figure 4A , lane 7), indicating a large difference in binding affinities. Even 1 nM RADX pre-bound to the DNA is sufficient to block binding by 10 mM RAD51 ( Figure 4A, lane 11) . At 20 mM RAD51, the 1-nM pre-bound RADX is partially displaced by RAD51 (Figure 4A, lane 13) . At the highest concentration of RADX that we tested (2 nM), the RADX-DNA complex resists displacement even with 20 mM RAD51 ( Figure 4A, lanes 17-19) . Conversely, when RAD51 is pre-bound to the DNA at micromolar concentrations, even 1 nM RADX is sufficient to displace most of the RAD51 ( Figure 4B ). Thus, RADX can outcompete RAD51 for ssDNA binding even when RAD51 is at 10,000-fold molar excess. This competition is dependent on the ability of RADX to bind DNA, because a RADX mutant that abrogates most of its DNA binding activity (OB-m RADX; Dungrawala et al., 2017) cannot compete with RAD51 for ssDNA ( Figures 4A, lanes 8-10, and 4C ). We also confirmed that RADX competes with RAD51 for ssDNA, utilizing a biotin-ssDNA pull-down assay in which pre-bound RAD51 is displaced by RADX ( Figure 4D ).
These results suggest that RADX and RAD51 compete for the same ssDNA ligand. RAD51 is abundantly expressed in both 293T and U2OS cells (2 3 10 6 molecules/cell in both cell types; Figures  4E and S4 ). On the other hand, RADX is expressed at comparatively low levels (1 3 10 5 molecules/cell in 293T and 13,000 molecules/cell in U2OS; Figure 4D ). Despite being 243 or 1703 less abundant than RAD51 in 293T or U2OS cells, respectively, the strong affinity of RADX for ssDNA suggests there is sufficient RADX in cells to inhibit RAD51 from binding ssDNA. Thus, additional regulatory mechanisms controlled by BRCA2 or other RAD51 mediator proteins are essential to overcome the antagonistic activities of RADX.
DISCUSSION
Our data indicate that loss of RADX mimics RAD51 overexpression and confers fork protection to cells lacking BRCA1/2, FANCA, FANCD2, or BOD1L-all situations where RAD51 filament stability is compromised. RADX loss prevents both DNA2-and MRE11-dependent fork degradation. Conversely, RADX overexpression mimics loss of BRCA1/2 and results in fork instability that is dependent on fork reversal. RADX can outcompete RAD51 for ssDNA even when present at concentrations that are 10,000-fold less than RAD51. There is less RADX per cell than RAD51, but even at these reduced concentrations, RADX would efficiently outcompete RAD51. Positive RAD51 regulators like BRCA2 are thus required to balance the antagonistic functions of RADX ( Figure 4F ).
The deleterious effects of both decreasing and increasing RADX expression levels and its relative stoichiometry with RAD51 are reminiscent of the relationship between the bacterial RecX and RecA proteins (Cox, 2007) . In contrast to RecX and RecA, we have not observed evidence for a trimeric complex between RADX, RAD51, and ssDNA. Thus far, our data are most consistent with a competition mechanism to explain how RADX antagonizes RAD51. However, we cannot rule out the possibility that a trimeric complex could be detectable using other experimental conditions. Furthermore, the ability of RADX to easily outcompete RAD51 for ssDNA binding biochemically may be modulated by other proteins or regulatory mechanisms in cells.
An alternative model for how RADX depletion causes fork protection would be for RADX to activate or recruit the fork degradation nucleases. We do not favor this model for the following reasons: first, there is no difference in the amount of MRE11 or DNA2 at replication forks in RADXD cells (Dungrawala et al., 2017) . Second, there is no difference in the amount of ssDNA or RPA S4/S8 phosphorylation upon RADX depletion (Dungrawala et al., 2017) . Third, RADX silencing does not cause sensitivity to ionizing radiation (Dungrawala et al., 2017) . Fourth, RADX silencing prevents both MRE11-and DNA2-dependent nascent strand degradation. Fifth, RADX silencing does not prevent the DNA2-dependent fork degradation caused by long HU treatments in U2OS cells with functional BRCA-RAD51. Finally, RADX overexpression causes decreased RAD51 accumulation in HU-or g-irradiation (IR)-treated cells (Dungrawala et al., 2017) , which would be the opposite of what would be expected if RADX promoted the activities of MRE11 and DNA2. Thus, we favor the model that RADX functions by directly or indirectly regulating RAD51.
Because RADX overexpression results in fork degradation, it must be insufficient to prevent the fork reversal function of RAD51 in the presence of persistent replication stress. Consistent with this idea, RADX overexpression results in only a partial decrease in RAD51 foci formation in HU-treated cells (Dungrawala et al., 2017) . Thus, similar to the loss of BRCA2, the partial decrease in RAD51 function by RADX overexpression is sufficient to cause defects in fork protection, but not in fork reversal unless combined with partial silencing of RAD51 expression.
Finally, we found that the amount of RAD51 function is critical to determining the fate of persistently stalled forks. Wild-type levels allow stalled forks to be reversed, which can serve as a way to accomplish template switching, repair DNA damage, or otherwise promote fork restart. Moderately reduced levels of RAD51 can still facilitate fork reversal but are unable to stabilize the reversed fork, leading to excessive nuclease-mediated resection and genome instability if forks are persistently stalled. Very low levels of RAD51 prevent any fork reversal, yielding stable nascent strands but defects in fork restart and challenges in completion of DNA replication. RADX helps to balance RAD51 activities, ensuring its fork reversal and protection activities operate appropriately to maintain genome stability.
Replication Fork Protection as a Determinant of Chemosensitivity Whether replication fork protection is an important determinant of PARP inhibitor and chemosensitivity appears to be dependent on genetic background and experimental model Ding et al., 2016; Dungrawala et al., 2017; Feng and Jasin, 2017; Yazinski et al., 2017) . For example, loss of some factors like EZH2 and MUS81 restores fork protection and chemoresistance only to BRCA2 mutant, but not BRCA1 mutant cells (Lemaç on et al., 2017; Rondinelli et al., 2017). Our results suggest RADX also differentiates between BRCA2 and BRCA1 because deleting RADX confers partial chemoresistance to BRCA2-deficient U2OS cells and not BRCA1-deficient U2OS cells despite rescuing fork protection in both settings. The specific HR gene mutation and its severity in disrupting function may determine whether restoring fork protection would be sufficient to generate drug resistance. Identifying drug-resistance mechanisms in patients will be critical to testing this idea.
EXPERIMENTAL PROCEDURES
Cell Culture U2OS, RPE-hTERT, and HEK293T cells were cultured in DMEM with 7.5% fetal bovine serum (FBS). Fibroblasts were cultured in DMEM with 15% FBS and 1% non-essential amino acids. Cells are tested for mycoplasma and authenticated using short tandem repeat profiling. U2OS RADXD-and RADX-overexpressing cells were described previously, and drug sensitivity assays were completed as described (Dungrawala et al., 2017) . Plasmid and siRNA transfections were performed with polyethylenimine, Dharmafect1 (Dharmacon) for U2OS, or RNAiMax (Thermo Fisher) for RPE and fibroblast cell lines. siRNAs and antibodies are described in Supplemental Experimental Procedures.
DNA Binding and DNA Fiber Assays RAD51 electrophoretic mobility shift assay (EMSA) was performed largely as described (Wang et al., 2015) . 0.5 nM 32 P-labeled oligo-dT50 ssDNA was incubated with RAD51 in 20 mL reactions of binding buffer containing 50 mM Tris (pH 7.5), 100 mg/mL BSA, 2 mM CaCl 2 , 2 mM ATP, 100 mM NaCl, and 1 mM DTT. The reactions were incubated at 37 C for 30 min. The reactions were separated on 5% 0.53 TBE 37.5:1 gels at 50 V for 180 min at 4 C.
The biotin-ssDNA pull-down assays utilized 4 mM RAD51 pre-bound to the DNA in the presence of 2 mM ATP and 0.1% Tween-20. Increasing amounts of RADX was added, and reactions were incubated for 30 min prior to separation of the DNA-bound and supernatant fractions and analysis by SDS-PAGE and immunoblotting.
DNA fiber analysis of DNA replication was carried out as described previously (Couch et al., 2013) .
Statistical Methods
All statistical analyses are described in the figure legends and were completed with Prism. Investigators were blinded to sample identities and all experiments completed at least twice.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at https://doi.org/ 10.1016/j.celrep.2018.06.061.
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